← Back to Search

Other

NRX194204 for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by NuRx Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 months
Awards & highlights

Study Summary

The purpose of this study is to determine whether NRX 194204 is effective in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC).

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall objective tumor response rate
Secondary outcome measures
Overall safety and toxicity of NRX 194204 in NSCLC patients
Overall survival
Progression free survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: NRX194204Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

NuRx Pharmaceuticals, Inc.Lead Sponsor
1 Previous Clinical Trials
65 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
2009. "Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00964132.
All > Lung > Sclc
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top